Non-Invasive Blood Pressure Monitors Market Witnesses R&D of Wearable Monitoring Devices

 

A critical need for health professionals is to monitor the cardiovascular function in critically ill patients. Such need led to the development of non-invasive blood pressure monitors. According to the American Heart Association's Heart and Stroke Statistics 2019 Update, around 48% of all adults in the U.S. suffered from some type of cardiovascular disease in 2016. Thus, high prevalence of cardiovascular diseases is expected to aid in growth of the non-invasive blood pressure monitors market.

Emergence of Covid-19 has prompted several regulatory changes regarding use of medical devices. These changes are expected to impact growth of the non-invasive blood pressure monitors market. Globally, as of 6:18pm CEST, 8 July 2021, there have been 184,820,132 confirmed cases of COVID-19, including 4,002,209 deaths, reported to WHO. As of 8 July 2021, a total of 3,032,217,959 vaccine doses have been administered. In March 2020, the U.S. Food and Drug Administration allowed expanded use of non-invasive remote patient monitoring devices to slow the spread of COVID-19. Some of the non-invasive remote-monitoring devices covered by the new guidance are electronic stethoscopes, non-invasive blood pressure devices, and respiratory rate/breathing frequency measurement devices.

R&D of new approaches is expected to offer lucrative growth opportunities for players in the non-invasive blood pressure monitors market. In July 2021, Movano Inc., a health technology company, received approval from the Institutional Review Board to conduct blood pressure studies on up to 200 participants in the Movano Clinical Lab, Recently, Movano used its non-invasive, iPhone-sized prototype device to collect pulse pressure waveform data.

The non-invasive blood pressure monitors market is witnessing R&D of wearable devices. In December 2020, the U.S. Patent and Trademark Office granted Apple, Inc. a major patent regarding a future Apple Watch feature that could monitor the blood pressure of a user. In June 2021, the U.S Food and Drug Administration approved Edwards Lifesciences’ AI finger sensor combo to predict dangerously low blood pressures. The company’s Acumen Hypotension Prediction Index software was initially cleared only for use with invasive arterial lines. However, now it can now be deployed alongside a finger cuff to predict drops in blood pressure. The company is looking forward to develop ICU-quality blood pressure monitors with a noninvasive upgrade to the usual arterial catheter.